Evommune, Inc. Capital Expenditures
Evommune, Inc. (EVMN) reported Capital Expenditures of $266.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Evommune, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $183.00K.
- Evommune, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $83.00K.
- Evommune, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $104.00K.
- Evommune, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $131.00K.
- Evommune, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $235.00K, a 167.05% increase from fiscal 2024.
- Evommune, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $88.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $183.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $266.00K 10-Q · filed 2026-08-06 | $370.00K derived: sum of 3 quarters · filed 2026-08-06 | $501.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $83.00K 10-Q · filed 2026-05-07 | $187.00K derived: sum of 2 quarters · filed 2026-05-07 | $318.00K derived: sum of 3 quarters · filed 2026-05-07 | $318.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $235.00K derived: sum of 2 quarters · filed 2026-03-05 | $235.00K derived: sum of 3 quarters · filed 2026-08-06 | $235.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | $131.00K derived: sum of 2 quarters · filed 2026-08-06 | $131.00K 10-Q · filed 2025-12-11 | $131.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $88.00K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $88.00K 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |